Compare Gilead Sciences, Inc. (GILD) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Main Street Capital Corporation — how do they compare? Gilead Sciences, Inc. trades at $136.02 (market cap $163.51B), while Main Street Capital Corporation trades at $55.44 (market cap $4.97B). The key difference: Gilead Sciences, Inc. is far larger — about 32.9× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.2%). Which is the better fit depends on your goals.
| GILD | MAIN | |
|---|---|---|
Market Cap | $163.51B | $4.97B |
Sector | Health | Financials |
52-Week High | $155.80 | $67.54 |
52-Week Low | $108.22 | $49.63 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MAIN trades at $55.24, up 4.05% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong profitability with an 81.08% net income margin and 14.37% ROE, though recent quarters saw mixed earnings results. Dividend payments remain consistent, supporting income appeal. Revenue declined to $592M in 2025 from $601M in 2024, with a projected further drop to $526M in 2026.
Outlook is cautiously optimistic with a consensus price target of $57.75 offering modest upside. Risks include earnings volatility and potential margin compression. Analyst sentiment leans neutral with 78.57% hold ratings, reflecting balanced near-term expectations amid softening revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
